Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Increased CD4+ T cell lineage commitment determined by CpG methylation correlates with better prognosis in urinary bladder cancer patients.

Ahlén Bergman E, Hartana CA, Johansson M, Linton LB, Berglund S, Hyllienmark M, Lundgren C, Holmström B, Palmqvist K, Hansson J, Alamdari F, Huge Y, Aljabery F, Riklund K, Winerdal ME, Krantz D, Zirakzadeh AA, Marits P, Sjöholm LK, Sherif A, Winqvist O.

Clin Epigenetics. 2018 Aug 3;10(1):102. doi: 10.1186/s13148-018-0536-6.

2.

Neoadjuvant Chemotherapy Reinforces Antitumour T cell Response in Urothelial Urinary Bladder Cancer.

Krantz D, Hartana CA, Winerdal ME, Johansson M, Alamdari F, Jakubczyk T, Huge Y, Aljabery F, Palmqvist K, Zirakzadeh AA, Holmström B, Riklund K, Sherif A, Winqvist O.

Eur Urol. 2018 Dec;74(6):688-692. doi: 10.1016/j.eururo.2018.06.048. Epub 2018 Jul 17.

PMID:
30025882
3.

Urothelial bladder cancer may suppress perforin expression in CD8+ T cells by an ICAM-1/TGFβ2 mediated pathway.

Hartana CA, Ahlén Bergman E, Zirakzadeh AA, Krantz D, Winerdal ME, Winerdal M, Johansson M, Alamdari F, Jakubczyk T, Glise H, Riklund K, Sherif A, Winqvist O.

PLoS One. 2018 Jul 2;13(7):e0200079. doi: 10.1371/journal.pone.0200079. eCollection 2018.

4.

Urinary Bladder Cancer Tregs Suppress MMP2 and Potentially Regulate Invasiveness.

Winerdal ME, Krantz D, Hartana CA, Zirakzadeh AA, Linton L, Bergman EA, Rosenblatt R, Vasko J, Alamdari F, Hansson J, Holmström B, Johansson M, Winerdal M, Marits P, Sherif A, Winqvist O.

Cancer Immunol Res. 2018 May;6(5):528-538. doi: 10.1158/2326-6066.CIR-17-0466. Epub 2018 Mar 27.

5.

Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer.

Zirakzadeh AA, Kinn J, Krantz D, Rosenblatt R, Winerdal ME, Hu J, Hartana CA, Lundgren C, Bergman EA, Johansson M, Holmström B, Hansson J, Sidikii A, Vasko J, Marits P, Sherif A, Winqvist O.

Clin Immunol. 2017 Mar;176:63-70. doi: 10.1016/j.clim.2016.12.003. Epub 2016 Dec 24.

PMID:
28025135
6.

The many flavors of tumor-associated B cells.

Marits P, Zirakzadeh AA, Sherif A, Winqvist O.

Oncoimmunology. 2013 Aug 1;2(8):e25237. Epub 2013 Jun 10.

7.

Response to comment on "multiplex B cell characterization in blood, lymph nodes, and tumors from patients with malignancies".

Marits P, Zirakzadeh AA, Sherif A, Winqvist O.

J Immunol. 2013 Nov 1;191(9):4471-2. doi: 10.4049/jimmunol.1390053. No abstract available.

8.

Multiplex B cell characterization in blood, lymph nodes, and tumors from patients with malignancies.

Zirakzadeh AA, Marits P, Sherif A, Winqvist O.

J Immunol. 2013 Jun 1;190(11):5847-55. doi: 10.4049/jimmunol.1203279. Epub 2013 Apr 29.

9.

The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation.

Hu J, Kinn J, Zirakzadeh AA, Sherif A, Norstedt G, Wikström AC, Winqvist O.

Clin Exp Immunol. 2013 Jun;172(3):490-9. doi: 10.1111/cei.12060.

Supplemental Content

Loading ...
Support Center